Help fight C-19 by signposting patients to clinical studies

Help fight C-19 by signposting patients to clinical studies

October 25, 2020

Community pharmacists and their teams are being encouraged to support the nation’s fight against COVID-19 by signposting patients with suspected or even confirmed SARS-COV-2 infection to the PRINCIPLE trial.

The PRINCIPLE trial platform is a UK-wide priority trial to find treatments for COVID-19 and the only one based in primary care.

It is designed to test a range of treatments in the community, with treatment arms that can be stopped, replaced or added. Currently it is evaluating usual care alone versus usual care plus azithromycin; or usual care plus doxycycline.

The trial is being run by the University of Oxford and is funded by UK Research and Innovation and the Department for Health and Social Care through the National Institute for Health Research.

Eligible patients are people with symptoms of COVID-like-illness who are:

  • aged 50 and over and have a comorbidity; or
  • who are aged 65 and over, with or without comorbidity.

They can be signposted to to register for the trial.

Pharmacies can support the recruitment of patients by signposting eligible patients to the trial website and by displaying a poster to highlight the potential for people to participate. Pharmacies can request promotional materials for the trial by completing a short Google form.

Further information on how pharmacy teams can support the research


Posted in: , ,

More Latest News >

Have you completed the DMS DoC?

Pharmacists and pharmacy technicians are reminded that they must complete the Discharge Medicines Service (DMS) Declaration of Competence (DoC) before...

FAQs on the HEE workforce survey

The 2021 Health Education England (HEE) Community Pharmacy Workforce Survey commenced today. PSNC encourages all pharmacy contractors to participate in...

April CPN magazine published

The April 2021 edition of PSNC’s Community Pharmacy News (CPN) is now available. This issue of CPN features: Negotiations begin...